Arena Pharmaceuticals Inc

Arena Pharmaceuticals — Corporate Update (September 2020)

13 slides from Arena Pharmaceuticals's corporate update, Sep 23, 2020

  1. Slide 1: Etrasimod IBD Program Update

    September 2020 Etrasimod IBD Program Update Exhibit 99.1

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements September 2020 • This presentation includes forward-looking statements that involve a number of risks and uncertainties, including statements about Arena’s business, catalysts, value, our investigative stage drug candidates, including with respect to their potential (inclu

  3. Slide 3: Etrasimod: Potential Best-in-Disease S1P Receptor Modulator with Broad Potential Applicability

    Etrasimod Potential Best-in-Disease S1P Receptor Modulator with Broad Potential Applicability Source: 1. Arena Quantitative Market Research, March 2018.; 2. Dahlhamer JM, et al. MMWR Morb Mortal Wkly Rep 2016;65:1166–1169.; 3. UC & CD Disease Landscape & Forecast Reports. DRG. 2018 60-80% $24B+ Mark

  4. Slide 4: Etrasimod Global Phase 3 Program in UC

    Etrasimod Global Phase 3 Program in UC Overview of Registration Program Moderately to Severely Active UC Endpoints Primary Endpoint Week 12, week 52 clinical remission (modified Mayo Clinic score) Primary Endpoint Week 12 clinical remission (modified Mayo Clinic score) 52-Week Treat-through Trial 12

  5. Slide 5: ELEVATE UC Program On Track To Readout Q4 2021

    ELEVATE UC Program On Track To Readout Q4 2021 ELEVATE UC 52 enrollment remains on track with completion of enrollment expected by end of Q4 2020, with ELEVATE UC Program topline data readout scheduled for Q4 2021 First patient dosed in ELEVATE UC 12 study confirms that the ELEVATE UC registrational

  6. Slide 6: Feedback From Stakeholders Has Identified a Significant Unmet Need in the UC Market

    Feedback From Stakeholders Has Identified a Significant Unmet Need in the UC Market Convenient Delivery Oral therapy with comparable efficacy to current biologics Durable Response Replace long-term use of anti-TNFs, which can lose effectiveness Trusted Option Beyond 5-ASA Safe, oral step-up therapy

  7. Slide 7: Market Research Supports Etrasimod as Potential Market Leader in UC Market

    Source: Arena data on file. Market Research Supports Etrasimod as Potential Market Leader in UC Market Future Preference „ Expanding Oral Market ¢ Novel Oral ¢ Biologics 81% S1P vs. JAK ¢ S1P Modulator ¢ JAK Inhibitor Etrasimod vs. Ozanimod ¢ Etrasimod ¢ Ozanimod 64% 32% September 2020 •

  8. Slide 8: Broad Group of Sub-Optimally Controlled Patients Eligible for Advanced Therapy

    Broad Group of Sub-Optimally Controlled Patients Eligible for Advanced Therapy, But Reluctant Due to Risk/Benefit Profile Symptom Worsening Aminosalicylate Corticosteroids / Immunosupressives Biologics Cyclosporine /JAKs Tacrolimus / Surgery Sub-optimal control on conventional Tx Advanced Tx Patient

  9. Slide 9: GLADIATOR-UC – Expected to Initiate Early 2021

    GLADIATOR-UC – Expected to Initiate Early 2021 Subject Screening: During ELEVATE UC enrollment period After ELEVATE UC completes enrollment MMS 4-9, with ES ≥ 2 & RB ≥1 MMS 4-6, with ES ≥ 1 MMS 4-6, with ES ≥ 1 September 2020 • MMS: Modified Mayo Score; ES: Endoscopic Score; RB: Rectal Bleeding

  10. Slide 10: Focus on Patients Sub-Optimally Controlled on Conventional Tx

    Focus on Patients Sub-Optimally Controlled on Conventional Tx Symptom Worsening Aminosalicylate Corticosteroids / Immunosupressives Biologics Cyclosporine /JAKs Tacrolimus / Surgery Sub-optimal control on conventional Tx Advanced Tx Patients Maintained Conventional Tx Patients September 2020 •

  11. Slide 11: Etrasimod Ph 2/3 Program in Crohn's Disease

    *Subjects who do not meet response criteria at Week 14 will enter a 6-week Extended Induction Period † Sub-studies 2, 3 and phase 3 induction will begin with both 2 and 3 mg doses until dose selection is determined at the completion of Sub-Study 1 ‡ Primary efficacy endpoints for Sub-study 2 and Pha

  12. Slide 12: Catalyst Horizon

    Catalyst Horizon New IND(s) APD418 Ph 1 Data Etrasimod AA Ph 2 Data Etrasimod ADVISE (AD) Ph 2b Data Etrasimod ELEVATE UC 52 Ph 3 Data APD418 Ph 2a Data H2 2020 H1 2021 H2 2021 H1 2022 H2 2022 COVID-19 IMPACTED / TIMELINES DEPENDENT ! Etrasimod CD Ph 3 Data Etrasimod CULTIVATE (CD) Ph 2 Data Olorina

  13. Slide 13: Arena Pharmaceuticals

    ARENA PHARMACEUTICALS Nasdaq: ARNA

Arena Pharmaceuticals — Corporate Update (September 2020) on 6ix